HairLabs Anti-Grey 1.0: What the Research Actually Shows
Independent evidence assessment — 13-ingredient anti-greying formula — March 2026
Formula Assessment: Weakly supported
Two ingredients (B12 and copper) have meaningful human evidence for premature greying, but only in people with a deficiency. The formula’s headline ingredient, luteolin, is supported by a single mouse study with no human trials, and the central anti-greying mechanism has never been tested in a human supplementation trial.
Formula Evidence Review
| Ingredient | Dose | Claim Made | Evidence Tier | Key Evidence | Verdict |
|---|---|---|---|---|---|
| Vitamin B12 | 100 μg | Methylation support; B12 deficiency linked to premature greying | Moderate | Case-control (Daulatabad 2017) + systematic review (Mahendiratta 2020); reversal in deficient patients documented | ⚠️ Partial support |
| Copper Gluconate | 1.5 mg | Tyrosinase cofactor; copper deficiency reduces melanin synthesis | Moderate | 2 of 3 case-control studies show lower serum copper in premature greying (Kil 2011, Chakrabarty 2018); no RCT of supplementation | ⚠️ Partial support |
| Ashwagandha | 300 mg | Reduces cortisol and stress that triggers greying | None | RCT evidence for cortisol reduction (Chandrasekhar 2012) but no human trial linking ashwagandha to grey hair outcomes | ℹ️ Nutritional role only |
| Folate (L-5-MTHF) | 400 μg | Methylation cycle support for melanocyte function | Weak | 1 of 2 case-control studies positive (Daulatabad 2017); likely confounded by co-occurring B12 deficiency; no intervention study | ℹ️ Nutritional role only |
| Vitamin D3 | 1,000 IU | Follicle signalling via vitamin D receptor | None | 2 of 3 observational studies show lower D3 in premature greying; no intervention evidence; no credible direct mechanism to melanogenesis | ℹ️ Nutritional role only |
| Biotin | 5,000 μg | Hair structure support | None | Deficiency association in PHG patients (Daulatabad 2017); no mechanistic pathway to melanogenesis; high dose interferes with immunoassay diagnostics | ℹ️ Nutritional role only |
| Vitamin B6 | 10 mg | Cofactor in tyrosine metabolism; oxidative defence | None | Single case report in homocystinuria (genetic disorder) at 500 mg; pharmacological dose, special population; not applicable to healthy adults | ℹ️ Nutritional role only |
| Vitamin C | 100 mg | Antioxidant — protects melanocytes from oxidative stress | None | No human trials for grey hair; antioxidant mechanism theoretically coherent but untested for this indication | ℹ️ Nutritional role only |
| Pantothenic Acid (B5) | 50 mg | Hair health; historical association with repigmentation | None | Historical uncontrolled case series only (pre-1960s); effective dose in those reports was 200 mg — four times the formula dose; PABA absent from formula | ℹ️ Nutritional role only |
| Choline | 100 mg | Methyl donor supporting SAM synthesis | None | No human trials; dose (100 mg) is ~20% of daily adequate intake; entirely theoretical for grey hair | ℹ️ Nutritional role only |
| Luteolin | 100 mg | Preserves melanocyte stem cells | None | One 2024 mouse study (Iida et al., Antioxidants 2024, 13:1549); no human trials; oral bioavailability in humans estimated 0–11% | ❌ Unsupported |
| L-Tyrosine | 500 mg | Melanin substrate | None | Animal model only (canine tyrosine-deficiency study); one unpublished human pilot trial registered but never published; substrate limitation not established in greying adults | ❌ Unsupported |
| Rhodiola Rosea | 100 mg | Adaptogen; stress reduction to prevent greying | None | In vitro evidence shows salidroside (primary active) inhibits melanin synthesis — opposite of intended effect; no human greying data | ❌ Unsupported |
Evidence tiers — Strong: multiple human RCTs | Moderate: some human evidence, limited | Weak: mainly animal/lab or inconsistent observational | None: no meaningful human evidence for this claim
✅ Supported | ⚠️ Partial support | ℹ️ Nutritional role only | ❌ Unsupported
Key Findings
- The headline ingredient, luteolin, rests on a single mouse study. Iida et al. 2024 is a well-designed animal study, but one mouse study does not establish benefit in humans. No human trials exist for luteolin and grey hair.
- Two ingredients have meaningful human links to premature greying — both via deficiency correction only. B12 and copper are the formula’s strongest-evidenced ingredients, but this evidence applies to people who are genuinely deficient, not replete adults.
- The central mechanism — melanocyte stem cell preservation — has never been tested in a human supplementation trial. This is the biological claim underlying the product; it has been studied in mice but not in humans with any oral supplement.
- One ingredient’s biochemical evidence points in the wrong direction. Rhodiola Rosea’s active compound, salidroside, is investigated as a melanogenesis inhibitor in vitro — meaning existing laboratory evidence suggests it may reduce melanin production, not preserve it.
- Most of the formula is nutritional insurance at standard doses. Many vitamins have recognised nutritional functions and reasonable doses, but none have direct anti-greying trial evidence in healthy adults.
What Works
Vitamin B12 is the best-evidenced ingredient in the formula for grey hair: multiple case-control studies consistently identify B12 deficiency as a risk factor for premature greying, and case reports document partial repigmentation after B12 replacement in deficient patients. Copper has plausible support from 2 of 3 case-control studies. The important caveat: both apply specifically to people who are deficient — there is no trial evidence for supplementation in B12- or copper-replete individuals.
What Doesn’t
Luteolin is marketed as the formula’s core innovation and the “melanocyte stem cell” claim is its headline mechanism. That claim rests on a single 2024 mouse study. This is the lowest level of translatable evidence available, and it has not been followed by any human trial. The melanocyte stem cell preservation mechanism — while real and well-documented in animal research — has never been demonstrated with an oral supplement in humans. Rhodiola’s inclusion is additionally problematic: the in vitro evidence for its primary active compound runs counter to the formula’s stated goal.
Bottom Line
Anti-Grey 1.0 contains a sensible nutritional base that would address common deficiencies in B12, copper, and several vitamins. For someone genuinely deficient in B12 or copper, the formula could correct the nutritional shortfall that research links to premature greying. However, the product’s marketing is built around luteolin’s claimed melanocyte stem cell preservation action — and that claim has no human evidence behind it. The central mechanism has been demonstrated in mice, not people. Consumers who are already nutritionally replete should have realistic expectations: this formula may provide general micronutrient insurance, but the specific anti-greying claims remain unsubstantiated by human trials.